GitLab Cl A had its Relative Strength (RS) Rating upgraded from 77 to 82 Friday.
IBD's proprietary rating identifies price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the best stocks often have an RS Rating of above 80 in the early stages of their moves.
Looking For The Best Stocks To Buy And Watch? Start Here
GitLab Cl A is trying to complete a cup without handle with a 78.53 entry. See if the stock can clear the breakout price in heavy volume.
While sales growth fell last quarter from 33% to 31%, EPS grew 1,400%, up from 0% in the previous report. The company is expected to report its latest earnings and sales numbers on or around Dec. 2.
GitLab Cl A holds the No. 2 rank among its peers in the Computer-Technical Services industry group. Globant is the No. 1-ranked stock within the group.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
